Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33436167.
- Also identified by DOI 10.1016/j.eururo.2020.12.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Optimisation of prostate-specific membrane antigen (PSMA) based radioligand therapy (RLT) requires a focus on prospective trials.
Medical subject headings
- Precision Medicine
- Prostate